Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 118 clinical trials
Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer

It is not yet known what level of complications x-ray therapy or proton beam radiation therapy have in treating patients with breast cancer.

prognostic stage iib breast cancer ajcc v8
anatomic stage iii breast cancer ajcc v8
anatomic stage i breast cancer ajcc v8
stage i breast cancer
stage iii breast cancer
  • 0 views
  • 05 Jan, 2021
Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies

The main purpose of this study is to evaluate the impact of food supplements (herbal remedies) on sign and symptoms induced by cancer therapies: Nettle will be administered for improvement of anemia and fatigue; Peppermint will be administered for improvement of nausea. Secondary aims of the trial are to evaluate …

immunomodulators
cyclophosphamide
vomit
adjuvant therapy
hormone therapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

human chorionic gonadotropin
hormone therapy
measurable disease
gonadotropin
cancer
  • 0 views
  • 16 Feb, 2024
  • 5 locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

breast cancer
erbb1
her2/neu-negative breast cancer
estrogen
epidermal growth factor receptor
  • 0 views
  • 16 Feb, 2024
  • 7 locations
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and safety of camrelizumab combined with radiotherapy in the treatment of early TNBC

absolute neutrophil count
triple-negative breast cancer
metastasis
cancer
serum bilirubin level
  • 0 views
  • 05 Aug, 2020
Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of ZW25 in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and ZW25 in combination with tislelizumab and chemotherapy in participants with HER2-positive gastric/gastroesophageal Junction (GEJ) adenocarcinoma

erbb2
adenocarcinoma
recurrent disease
measurable disease
epidermal growth factor
  • 0 views
  • 16 Feb, 2024
  • 12 locations
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

immunomodulators
keytruda
liver metastasis
periodic abstinence
measurable disease
  • 8 views
  • 05 Aug, 2020
NBE-002 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

carcinoma
advanced solid tumor
triple-negative breast cancer
measurable disease
anthracyclines
  • 0 views
  • 05 Aug, 2020
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

immunomodulators
breast irradiation
adjuvant therapy
anticoagulants
immunohistochemistry
  • 0 views
  • 16 Feb, 2024
  • 1 location
  • 0 views
  • 06 Dec, 2023
  • 2 locations